20,700 Shares in Keros Therapeutics, Inc. (NASDAQ:KROS) Bought by Erste Asset Management GmbH

Erste Asset Management GmbH bought a new position in shares of Keros Therapeutics, Inc. (NASDAQ:KROS - Free Report) in the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund bought 20,700 shares of the company's stock, valued at approximately $1,169,000. Erste Asset Management GmbH owned approximately 0.05% of Keros Therapeutics as of its most recent SEC filing.

A number of other institutional investors have also added to or reduced their stakes in KROS. KBC Group NV increased its position in shares of Keros Therapeutics by 52.0% during the 3rd quarter. KBC Group NV now owns 1,263 shares of the company's stock valued at $73,000 after purchasing an additional 432 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. lifted its holdings in shares of Keros Therapeutics by 26.0% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,357 shares of the company's stock worth $77,000 after acquiring an additional 280 shares during the last quarter. Values First Advisors Inc. bought a new position in shares of Keros Therapeutics during the 3rd quarter valued at $89,000. Point72 Asia Singapore Pte. Ltd. purchased a new position in Keros Therapeutics in the 2nd quarter worth $128,000. Finally, LMR Partners LLP bought a new stake in Keros Therapeutics in the third quarter worth $213,000. 71.56% of the stock is currently owned by institutional investors.

Keros Therapeutics Trading Up 8.8 %

KROS traded up $5.51 during trading on Wednesday, hitting $67.79. 527,594 shares of the company's stock traded hands, compared to its average volume of 375,449. The stock has a market capitalization of $2.75 billion, a price-to-earnings ratio of -13.01 and a beta of 1.20. The company's 50 day simple moving average is $59.89 and its two-hundred day simple moving average is $52.48. Keros Therapeutics, Inc. has a 12-month low of $27.31 and a 12-month high of $73.00.

Keros Therapeutics (NASDAQ:KROS - Get Free Report) last posted its earnings results on Wednesday, November 6th. The company reported ($1.41) EPS for the quarter, missing analysts' consensus estimates of ($1.28) by ($0.13). The company had revenue of $0.39 million during the quarter. Keros Therapeutics had a negative return on equity of 41.74% and a negative net margin of 27,890.94%. The company's revenue for the quarter was up 4750.0% compared to the same quarter last year. During the same period in the previous year, the business posted ($1.33) earnings per share. On average, equities analysts expect that Keros Therapeutics, Inc. will post -5.28 EPS for the current year.

Analyst Ratings Changes

A number of research firms have recently weighed in on KROS. Scotiabank assumed coverage on Keros Therapeutics in a research note on Wednesday, October 16th. They issued a "sector outperform" rating and a $77.00 target price for the company. Jefferies Financial Group began coverage on shares of Keros Therapeutics in a report on Tuesday, November 5th. They set a "buy" rating for the company. Guggenheim reiterated a "buy" rating on shares of Keros Therapeutics in a research report on Wednesday. Wedbush reaffirmed an "outperform" rating and set a $84.00 price objective on shares of Keros Therapeutics in a research report on Thursday, November 7th. Finally, Bank of America decreased their target price on Keros Therapeutics from $81.00 to $76.00 and set a "buy" rating for the company in a research report on Thursday, September 12th. Twelve analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Keros Therapeutics presently has an average rating of "Buy" and a consensus price target of $88.89.

Keros Therapeutics Profile

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.